Angiogenic Inhibitors Modulate DIPG Tumor Growth

Alisertib (MedChemExpress, Monmouth Junction, NJ), bortezomib (MedChemExpress), panobinostat (MedChemExpress), ponatinib (MedChemExpress), MSN1-Leu (synthesized in our lab, [20 (link)]) were sterilely prepared and dissolved in 0.5% DMSO and sterile PBS. Bevacizumab (SelleckChem) is water soluble, and was directly dissolved in sterile PBS. Drugs were administered by pipetting 15μL of drug solution directly on top of (but not contacting) the CAM tumor on embryonic development day 11, 13, 15. Each experiment contained 1–5 biological replicates per treatment group (at time of ultrasound) and there were at least three experimental replicates for each drug (n = 3–24 per drug treatment). Vehicle treatments (0.5% DMSO in sterile PBS) from all drug experimental replicates were combined to form one large vehicle group for further analysis (DIPGXIIIp* n = 38, DIPGIV n = 19).